Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2014 Mar 17;25(3):272-81. doi: 10.1016/j.ccr.2014.02.017.

Dragging ras back in the ring.

Author information

1
Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, P.O. Box B, Frederick, MD 21702, USA.
2
Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, P.O. Box B, Frederick, MD 21702, USA; UCSF Helen Diller Family Comprehensive Cancer Center, Room 371, 1450 3(rd) Street, P.O. Box 589001, San Francisco, CA 94158-9001, USA. Electronic address: mccormic@cc.ucsf.edu.

Abstract

Ras proteins play a major role in human cancers but have not yielded to therapeutic attack. Ras-driven cancers are among the most difficult to treat and often excluded from therapies. The Ras proteins have been termed "undruggable," based on failures from an era in which understanding of signaling transduction, feedback loops, redundancy, tumor heterogeneity, and Ras' oncogenic role was poor. Structures of Ras oncoproteins bound to their effectors or regulators are unsolved, and it is unknown precisely how Ras proteins activate their downstream targets. These knowledge gaps have impaired development of therapeutic strategies. A better understanding of Ras biology and biochemistry, coupled with new ways of targeting undruggable proteins, is likely to lead to new ways of defeating Ras-driven cancers.

PMID:
24651010
DOI:
10.1016/j.ccr.2014.02.017
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center